Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus Betacoronavirus, is a pandemic virus, which has caused numerous fatalities, particularly in the elderly and persons with underlying morbidities. At present, there are no approved vaccines nor antiviral therapies available. The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role in the assessment of the immune status of convalescent COVID-19 patients, evaluation of recombinant therapeutic antibodies, and the evaluation of novel vaccines. To detect SARS-CoV-2-neutralizing antibodies, classically, a virus-neutralization test has to be performed at biosafety level 3, considerably limiting the general use of this test. In the present work, a biosafety level 1 pseudotype virus assay based on a propagation-incompetent vesicular stomatitis virus (VSV) has been used to determine the neutralizing antibody titers in convalescent COVID-19 patients. The neutralization titers in serum of two independently analyzed patient cohorts were available within 18 h and correlated well with those obtained with a classical SARS-CoV-2 neutralization test (Pearson correlation coefficients of r = 0.929 and r = 0.939, respectively). Most convalescent COVID-19 patients had only low titers of neutralizing antibodies (ND50 < 320). The sera of convalescent COVID-19 patients also neutralized pseudotype virus displaying the SARS-CoV-1 spike protein on their surface, which is homologous to the SARS-CoV-2 spike protein. In summary, we report a robust virus-neutralization assay, which can be used at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 patients and vaccinated individuals.
| Errataetall: |
CommentIn: Swiss Med Wkly. 2021 Aug 10;151:w20550. - PMID 34375986 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Vaccines - 8(2020), 3 vom: 15. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zettl, Ferdinand [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 12.08.2021 published: Electronic CommentIn: Swiss Med Wkly. 2021 Aug 10;151:w20550. - PMID 34375986 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines8030386 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312560265 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312560265 | ||
| 003 | DE-627 | ||
| 005 | 20231225144655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines8030386 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312560265 | ||
| 035 | |a (NLM)32679691 | ||
| 035 | |a (PII)E386 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zettl, Ferdinand |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: Swiss Med Wkly. 2021 Aug 10;151:w20550. - PMID 34375986 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus Betacoronavirus, is a pandemic virus, which has caused numerous fatalities, particularly in the elderly and persons with underlying morbidities. At present, there are no approved vaccines nor antiviral therapies available. The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role in the assessment of the immune status of convalescent COVID-19 patients, evaluation of recombinant therapeutic antibodies, and the evaluation of novel vaccines. To detect SARS-CoV-2-neutralizing antibodies, classically, a virus-neutralization test has to be performed at biosafety level 3, considerably limiting the general use of this test. In the present work, a biosafety level 1 pseudotype virus assay based on a propagation-incompetent vesicular stomatitis virus (VSV) has been used to determine the neutralizing antibody titers in convalescent COVID-19 patients. The neutralization titers in serum of two independently analyzed patient cohorts were available within 18 h and correlated well with those obtained with a classical SARS-CoV-2 neutralization test (Pearson correlation coefficients of r = 0.929 and r = 0.939, respectively). Most convalescent COVID-19 patients had only low titers of neutralizing antibodies (ND50 < 320). The sera of convalescent COVID-19 patients also neutralized pseudotype virus displaying the SARS-CoV-1 spike protein on their surface, which is homologous to the SARS-CoV-2 spike protein. In summary, we report a robust virus-neutralization assay, which can be used at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 patients and vaccinated individuals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a passive immunization | |
| 650 | 4 | |a pseudovirus | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Meister, Toni Luise |e verfasserin |4 aut | |
| 700 | 1 | |a Vollmer, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Bastian |e verfasserin |4 aut | |
| 700 | 1 | |a Steinmann, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Krawczyk, Adalbert |e verfasserin |4 aut | |
| 700 | 1 | |a V'kovski, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Todt, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Steinmann, Eike |e verfasserin |4 aut | |
| 700 | 1 | |a Pfaender, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Zimmer, Gert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 8(2020), 3 vom: 15. Juli |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:3 |g day:15 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines8030386 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 3 |b 15 |c 07 | ||